Why Corcept Therapeutics is a Great Value Stock to Buy

This post was originally published on this site

If people don’t have enough cortisol or too much, the body will be negatively impacted. Too little cortisol can lead to conditions such as shock, while too much cortisol can lead to a weakened immune response. CORT believes that the regulation of cortisol can be crucial to treating several diseases.

It’s only marketed drug, Korlym, is approved for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Korlym was actually the first drug approved by the Food and Drug Administration for patients with Cushing’s syndrome. Plus, unlike other drugs, Korlym only modulates cortisol. It does not stop its production, as that could cause harm to patients.

Continue reading on StockNews

Add Comment